Fig. 8
The downregulation of SLC2A1-AS1 suppresses tumor growth and glycolysis in vivo in EC9706 cells xenografted nude mice. A. Representative image of mice from each group after treatment with chemically modified NC or SLC2A1-AS1 siRNA. B. Tumor volumes are measured twice a week for assessment of therapeutic efficacy of SLC2A1-AS1 siRNA in EC9706 cells xenografted nude mice. C. The body weight of mice is determined twice a week in EC9706 cells xenografted nude mice. D. The expression of SLC2A1-AS1 is detected after the end of therapy by qRT-PCR in tumor tissues of nude mice. E. The miR-378a-3p level is examined at the end of therapy by qRT-PCR in nude mice tumor tissues. F. Western blot assay for the expressions of Glut1, HK2, PFKM, PKM and LDHA proteins in NC group and SLC2A1-AS1 siRNA group, and β-actin is used as loading control. G. Quantification of the relative levels of Glut1, HK2, PFKM, PKM and LDHA proteins in NC group and SLC2A1-AS1 siRNA group. H. Representative image of mice from each group after treatment with 2.5 μg pcDNA3.1 or pcDNA3.1-SLC2A1-AS1. I. Tumor volumes are measured twice a week for assessment of therapeutic efficacy of pcDNA3.1-SLC2A1-AS1 in EC9706 cells xenografted nude mice. J. The body weight of mice is determined twice a week in EC9706 cells xenografted nude mice. K. The expression of SLC2A1-AS1 is detected after the end of therapy by qRT-PCR in tumor tissues of nude mice. L. The miR-378a-3p level is examined at the end of therapy by qRT-PCR in nude mice tumor tissues. M. Western blot assay for the expressions of Glut1, HK2, PFKM, PKM and LDHA proteins in pcDNA3.1 group and pcDNA3.1-SLC2A1-AS1 group, and β-actin is utilized as loading control. N. Quantification of the relative levels of Glut1, HK2, PFKM, PKM and LDHA proteins in pcDNA3.1 group and pcDNA3.1-SLC2A1-AS1 group. Compared to NC group or pcDNA3.1 group, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 were regarded as statistical significance. Note: 1: NC; 2: SLC2A1-AS1 siRNA; 3: pcDNA3.1; 4: pcDNA3.1-SLC2A1-AS1